The main focus of the research group is in translational research in gynaecological cancers. In particular biomarker discovery and development (specifically immunological markers) in ovarian and endometrial cancers. The biomarkers are now in the process of being tested for diagnosis and surgical prognosis. The concept of predicting surgical outcome in ovarian cancer is a step in developing personalised medicine and providing patients with best care possible.
Recent advances in oncolgy have improved survival in patients with cancer but research into surgery may have additional benefits for the patient. Clinical research into optimal treatment of cervival preinvasive lesions has been a focus. We have shown that clear margins of resection has a significant effect on reducing risk of recurrence from preinvasive disease.
et al., 2021, The application of metabolomics in ovarian cancer management: a systematic review., Int J Gynecol Cancer, Vol:31, Pages:754-774
et al., 2021, Uterine Transplantation: Scientific Impact Paper No. 65 April 2021., Bjog
et al., 2021, Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis., Human Reproduction, Vol:36, ISSN:0268-1161, Pages:1093-1107
et al., 2021, A Novel Application of Calcium Electroporation to Cutaneous Manifestations of Gynaecological Cancer, European Journal of Gynecological Oncology, ISSN:0392-2936
et al., 2021, British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom, International Journal of Gynecological Cancer, Vol:31, ISSN:1048-891X, Pages:272-278